Reduction of Burn Progression and Scar Contracture with Cytokine-Neutralizing Gels
Profile last edited on: 7/25/2013

Total Award Amount
Award Phase
Principal Investigator
Newell R Washburn
Activity Indicator

Company Information

Washburn Therapeutics Inc

6743 Wilkins Avenue
Pittsburgh, PA 15217
Multiple Locations:   
Congressional District:   18
County:   Allegheny

Phase I

Phase I year
Phase I Amount
Washburn Therapeutics Inc. is developing biologically active gels that control inflammation by selectively neutralizing pro-inflammatory cytokines based on a technology being licensed exclusively by the company from Carnegie Mellon University. Preliminary results demonstrated that conjugates of antibodies against tumor necrosis factor-alpha and hyaluronic acid were able to reduce secondary necrosis in a partial-thickness rat burn model by 70%. This SBIR Phase I will focus on treating partial-thickness burns to test of the safety and efficacy of the technology in preventing extensive tissue necrosis following burn and measuring subsequent scar contraction in the rat burn model. The hypothesis of this research program is that prevention of burn progression through local control of inflammatory responses will improve healing outcomes. Early therapeutic intervention could make a significant impact in burn treatment.

Antibodies, Burns, Cytokines, Hyaluronic Acid, Inflammation, Scars

Phase II

Phase II year
Phase II Amount